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To present the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 88 
conceptual approach to the assessment of certainty of evidence from modelling studies (i.e. 89 
certainty associated with model outputs).  90 
Study Design and Setting: 91 
Expert consultations and, an international multi-disciplinary workshop informed development of a 92 
conceptual approach to assessing the certainty of evidence from models within the context of 93 
systematic reviews, health technology assessments, and health care decisions.  The discussions 94 
also clarified selected concepts and terminology used in the GRADE approach and by the 95 
modelling community. Feedback from experts in a broad range of modelling and health care 96 
disciplines addressed the content validity of the approach.  97 
Results: 98 
Workshop participants agreed, that the domains determining the certainty of evidence previously 99 
identified in the GRADE approach (risk of bias, indirectness, inconsistency, imprecision, reporting 100 
bias, magnitude of an effect, dose-response relation, and the direction of residual confounding) 101 
also apply when of assessing the certainty of evidence from models. The assessment depends on 102 
the nature of model inputs and the model itself and on whether one is evaluating evidence from a 103 
single model or multiple models. We propose a framework for selecting the best available 104 
evidence from models: 1) developing de novo a model specific to the situation of interest, 2) 105 
identifying an existing model the outputs of which provide the highest certainty evidence for the 106 
situation of interest, either “off the shelf” or after adaptation, and 3) using outputs from multiple 107 
models. We also present a summary of preferred terminology to facilitate communication among 108 
modelling and health care disciplines.   109 
Conclusions: 110 
This conceptual GRADE approach provides a framework for using evidence from models in health 111 
decision making and the assessment of certainty of evidence from a model or models. The GRADE 112 
Working Group and the modelling community are currently developing the detailed methods and 113 
related guidance for assessing specific domains determining the certainty of evidence from 114 
models across health care-related disciplines (e.g. therapeutic decision-making, toxicology, 115 
environmental health, health economics). 116 
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Introduction 118 
 119 
When direct evidence to inform health decisions is not available or not feasible to measure (e.g. 120 
long-term effects of interventions or when studies in certain populations are perceived as 121 
unethical), modelling studies may be used to predict that “evidence” and inform decision-122 
making.[1, 2] Health decision makers arguably face many more questions than can be reasonably 123 
answered with studies that directly measure the outcomes. Modelling studies, therefore, are 124 
increasingly used to predict disease dynamics and burden, the likelihood that an exposure 125 
represents a health hazard, the impact of interventions on health benefits and harms, or the 126 
economic efficiency of health interventions, among others [1]. Irrespective of the modelling 127 
discipline, decision makers need to know the best estimates of the modelled outcomes and how 128 
much confidence they may have in each estimate.[3] Knowing to what extent one can trust the 129 
outputs of a model is necessary when using them to support health decisions [4].  130 
 131 
Although a number of guidance documents on how to assess the trustworthiness of estimates 132 
obtained from models in several health fields have been previously published [5-16], they are 133 
limited by failing to distinguish methodological rigor from completeness of reporting, and by 134 
failing to clear distinguish among various components affecting the trustworthiness of model 135 
outputs. In particular they lack clarity regarding sources of  uncertainty that may arise from model 136 
inputs and from the uncertainty about a model itself. Modellers and those using results from 137 
models should assess the credibility of both.[4]  138 
 139 
Authors have attempted to develop tools to assess model credibility, but many addressed only 140 
selected aspects, such as statistical reproducibility of data, the quality of reporting[17], or a 141 
combination of reporting with aspects of good modelling practices[7, 18-21]. Many tools also do 142 
not provide sufficiently detailed guidance on how to apply individual domains or criteria. There is 143 
therefore a need for further development and validation of such tools in specific disciplines. 144 
Sufficiently detailed guidance for making and reporting these assessments is also necessary.  145 
 146 
Models predict outcomes based on model inputs – previous observations, knowledge and 147 
assumptions about the situation being modelled. Thus, when developing new models or assessing 148 
whether an existing model has been optimally developed, one should specify a priori the most 149 
appropriate and relevant data sources to inform different parameters required for the model. 150 
These may be either (seldom) a single study that provides the most direct information for the 151 
situation being modelled or (more commonly) a systematic review of multiple studies that identify 152 
all relevant sources of data. The risk of bias, directness and consistency of input data, precision of 153 
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Development, and Evaluation (GRADE) approach determine the certainty of each of the model 155 
inputs.[22-28] 156 
 157 
When assessing the evidence generated, various disciplines in health care and related areas that 158 
use modelling face similar challenges may benefit from shared solutions. Table 1  presents 159 
examples of selected models used in health-related disciplines in Table 1. Building on the existing 160 
GRADE approach, werefined and expand guidance regarding assessment of the certainty of model 161 
outputs. We formed a GRADE project group comprised of individuals with expertise in developing 162 
models and using model results in health-related disciplines, to create a unified framework for 163 
assessing the certainty of model outputs in the context of systematic reviews [29], health 164 
technology assessments, health care guidelines, and other health decision-making. In this article, 165 
we outline the proposed conceptual approach and clarify key terminology (Table 2). The target 166 
audience for this article includes researchers who develop models and those who use models to 167 
inform health care-related decisions. 168 
 169 
What we mean by a model 170 
 171 
Authors have used the term model to describe a variety of different concepts [2] and suggested 172 
several broader or narrower definitions [6, 30], so even modellers in the relatively narrow context 173 
of health sciences can differ in their views regarding what constitutes a model. Models vary in 174 
their structure and degree of complexity. A very simple model might be an equation estimating a 175 
variable not directly measured, such as the absolute effect of an intervention estimated as the 176 
product of the intervention’s relative effect and the assumed baseline risk in a defined population 177 
(risk difference equals relative risk reduction multiplied by an assumed baseline risk). On the other 178 
end of the spectrum, elaborate mathematical models, such as system dynamics models (e.g. 179 
infectious disease transmission) may contain dozens of sophisticated equations that require 180 
considerable computing power to solve. 181 
 182 
By their nature, such models only resemble the phenomena being modelled – i.e. specific parts of 183 
the world that are interesting in the context of a particular decision – with necessary 184 
approximations and simplifications, and to the extent that one actually knows and understands 185 
the underlying mechanisms.[1] Given the complexity of the world, decision-makers often rely on 186 
some sort of a model to answer health-related questions.  187 
 188 
In this article, we focus on quantitative mathematical models defined as “mathematical 189 
framework representing variables and their interrelationships to describe observed phenomena or 190 
predict future events”[30] used in health-related disciplines for decision-making (Table 1). These 191 
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predicting outcomes from input data (aka empirical models), and models combining mechanistic 193 
with empirical approaches (aka hybrid models). We do not consider here statistical models used to 194 
estimate the associations between measured variables (e.g. proportional hazards models or 195 
models used for meta-analysis). 196 
 197 
The GRADE approach 198 
 199 
The GRADE working group was established in the year 2000 and continues as a community of 200 
people striving to create systematic, and transparent frameworks for assessing and 201 
communicating the certainty of the available evidence used in making decisions in healthcare and 202 
health-related disciplines.[31] The GRADE Working Group now includes over 600 active members 203 
from 40 countries and serves as a think tank for advancing evidence-based decision-making in 204 
multiple health-related disciplines (www.gradeworkinggroup.org). GRADE is widely used 205 
internationally by over 110 organizations to address topics related to clinical medicine, public 206 
health, coverage decisions, health policy, and environmental health.  207 
 208 
The GRADE framework uses concepts familiar to health scientists, grouping specific items to 209 
evaluate the certainty of evidence in conceptually coherent domains. Specific approaches to the 210 
concepts may differ depending on the nature of the body of evidence (Table 2). GRADE domains 211 
include concepts such as risk of bias[28], directness of information [24], precision of an 212 
estimate[23], consistency of estimates across studies[25], risk of bias related to selective 213 
reporting[26], strength of the association, presence of a dose-response gradient, and the presence 214 
of plausible residual confounding that can increase confidence in estimated effects[27].  215 
 216 
The general GRADE approach is applicable irrespective of health discipline. It has been applied to 217 
rating the certainty of evidence for management interventions, health care related tests and 218 
strategies [32, 33], prognostic information[34], evidence from animal studies[35], use of resources 219 
and cost-effectiveness evaluations[36], and values and preferences[37, 38].  Although the GRADE 220 
Working Group has begun to address certainty of modelled evidence in the context of test-221 
treatment strategies[39], health care resource use and costs[36], and environmental health[40], 222 
more detailed guidance is needed for complex models such as those used in infectious diseases, 223 




On May 15 and 16, 2017, health scientists participated in a GRADE modelling project group 228 
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principles for the application of the GRADE assessment of certainty of evidence to modelled 230 
outputs. The National Toxicology Program of the Department of Health and Human Services in the 231 
USA and the MacGRADE Center in the Department of Health Research Methods, Evidence, and 232 
Impact at McMaster University sponsored the workshop which was co-organized by MacGRADE 233 
Center and ICF International.  234 
 235 
Workshop participants were selected to ensure a broad representation of all modelling related 236 
fields (Appendix). Participants had expertise in modelling in the context of clinical practice 237 
guidelines, public health, environmental health, dose-response modelling, physiologically based 238 
pharmacokinetic (PBPK) modelling, environmental chemistry, physical/chemical property 239 
prediction, evidence integration, infectious disease, computational toxicology, exposure 240 
modelling, prognostic modelling, diagnostic modelling, cost effectiveness modelling, biostatistics, 241 
and health ethics. 242 
 243 
Leading up to the workshop, we held three webinars to introduce participants to the GRADE 244 
approach. Several workshop participants (VM, KT, JB, AR, JW, JLB, HJS) collected and summarized 245 
findings from literature and the survey of experts as background material that provided a starting 246 
point for discussion. The materials included collected terminology representing common concepts 247 
across multiple disciplines that relate to evaluating modelled evidence, and a draft framework for 248 
evaluating modelled evidence. Participants addressed specific tasks in small groups and large 249 
group discussion sessions and agreed on key principles both during the workshop and through 250 






Workshop participants agreed on the importance of clarifying terminology to facilitate 257 
communication among modellers, researchers, and users of model outputs from different 258 
disciplines. Modelling approaches evolved somewhat independently, resulting in different terms 259 
being used to describe the same or very similar concepts or the same term being used to describe 260 
different concepts. For instance, the concept of extrapolating from the available data to the 261 
context of interest has been referred to as directness, applicability, generalizability, relevance, or 262 
external validity. The lack of standardized terminology leads to confusion and hinders effective 263 
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Overcoming these obstacles would require clarifying the definitions of concepts and agreeing on 266 
terminology across disciplines. Realizing that this involves changing established customary use of 267 
terms in several disciplines, workshop participants suggested accepting the use of alternative 268 
terminology while always being clear about the preferred terms to be used and the underlying 269 
concept to which it refers (Table 2). Experts attending a World Health Organization's consultation 270 
have very recently suggested a more extensive set of terms [41]. To facilitate future 271 
communication, participants of this workshop will further collaborate to build a comprehensive 272 
glossary of terminology related to modelling. 273 
 274 
Outline of an approach to using model outputs for decision making 275 
 276 
Workshop participants suggested an approach to incorporate model outputs in health-related 277 
decision making (Figure 1). In this article we describe only the general outline of the suggested 278 
approach – in subsequent articles we will discuss the details of the approach and provide more 279 
specific guidance on its application to different disciplines and contexts.  280 
 281 
Researchers should start by conceptualizing the problem and the ideal target model that would 282 
best represent the actual phenomenon or decision problem they are considering [13]. This 283 
conceptualization would either guide the development of a new model or serve as a reference 284 
against which existing models could be compared. The ideal target model should reflect: 1) the 285 
relevant population (e.g., patients receiving some diagnostic procedure or exposed to some 286 
hazardous substance), 2) the exposures or health interventions being considered, 3) the outcomes 287 
of interest in that context, and 4) their relationships. [42]. Conceptualizing the model will also 288 
reduce the risk of intentional or unintentional development of data-driven models, in which inputs 289 
and structure would be determined only by what is feasible to develop given the available data at 290 
hand.   291 
 292 
Participants identified 3 options in which users may incorporate model outputs in health decision-293 
making (Figure 1): 294 
1. Develop a model de novo designed specifically to answer the very question at hand. 295 
Workshop participants agreed that in an ideal situation such an approach would almost always 296 
be the most appropriate. Following this approach, however, requires suitable skills, ample 297 
resources, and time being available. It also requires enough knowledge about the 298 
phenomenon being modelled to be able to tell whether or not the new model would have any 299 
advantage over already existing models. 300 
2. Search for an existing model describing the same or a very similar problem and use it “off-301 
the-shelf” or adapt it appropriately in order to answer the current question. In practice many 302 
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model. However, it is often not possible to find an existing model that would be directly 304 
relevant to the problem at hand and/or it is not feasible to adapt an existing model when 305 
found. Any adaptation of a model requires availability of input data relevant for current 306 
problem, appropriate expertise and resources, and access to the original model. The latter is 307 
often not available (e.g. proprietary model or no longer maintained) or the structure of the 308 
original model is not being transparent enough to allow adaptation (“black-box”).  309 
3. Use the results from multiple existing models found in the literature [43]. This approach may 310 
be useful when a limited knowledge about the phenomenon being modelled makes it 311 
impossible to decide which of the available models is more relevant, or when many alternative 312 
models are relevant but use different input parameters. In such situations, one may be 313 
compelled to rely on the results of several models, because selection of the single, seemingly 314 
“best” model may provide incorrect estimates of outputs and lead to incorrect decisions. 315 
Identifying existing models that are similar to the ideal target model often requires performing a 316 
scoping of the literature or a complete systematic review of potentially relevant models – a 317 
structured process following a standardized set of methods with a goal to identify and assess all 318 
available models that are accessible, transparently reported, and fulfil the pre-specified eligibility 319 
criteria based on the conceptual ideal target model. Some prefer the term systematic survey that 320 
differs from a systematic review in the initial intention to use the results: in systematic reviews the 321 
initial intention is to combine the results across studies either statistically through a meta-analysis 322 
or narratively summarizing their results when appropriate, whereas in a systematic survey the 323 
initial intention is to examine the various ways that an intervention or exposure has been 324 
modelled, to review the input evidence that has been used, and ultimately to identity a single 325 
model that fits the conceptual ideal target model the best or requires the least adaptation; only 326 
when one cannot identify a single such model will it be necessary to use the results of multiple 327 
existing models. 328 
 329 
If a systematic search revealed one or more models meeting the eligibility criteria, then 330 
researchers would assess the certainty of outputs from each model. Depending on this 331 
assessment, researchers may be able to use the results of a single most direct and lowest risk of 332 
bias model “off-the-shelf” or proceed to adapt that model. If researchers failed to find an existing 333 
model that would be sufficiently direct and low risk of bias, then they would ideally develop their 334 
own model de novo.  335 
  336 
Assessing the certainty of outputs from a single model 337 
 338 
When researchers develop their own model or when they identify a single model that is 339 
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outputs (i.e. evidence generated from that model). Note, that if a model estimates multiple 341 
outputs, researchers needs to assess the certainty of each output separately [23-28]. Workshop 342 
participants agreed that all GRADE domains are applicable to assess the certainty of model 343 
outputs, but further work is needed to identify examples and develop specific criteria to be 344 
assessed, which may differ depending on the model being used and/or situation being modelled. 345 
 346 
Risk of bias in a single model 347 
 348 
The risk of bias of model outputs (i.e. model outputs being systematically overestimated or 349 
underestimated) is determined by the credibility of a model itself and the certainty of evidence for 350 
each of model inputs. 351 
 352 
The credibility of a model, also referred to as the quality of a model (Table 2) is influenced by its 353 
conceptualization, structure, calibration, validation, and other factors. Determinants of model 354 
credibility are likely to be specific to a modelling discipline (e.g., health economic models have 355 
different determinants of their credibility than PBPK models). There are some discipline-specific 356 
guidelines or checklists developed for the assessment of credibility of a model and other factors 357 
affecting the certainty of model outputs such as the framework to assess adherence to good 358 
practice guidelines in decision-analytic modelling [18], the questionnaire to assess relevance and 359 
credibility of modelling studies [18, 44, 45], good research practices for modelling in health 360 
technology assessment [5, 6, 8, 9, 12-14], the approaches to assessing uncertainty in read-across 361 
[46], and the quantitative structure-activity relationships [47] in predictive toxicology. Workshop 362 
participants agreed that there is a need for comprehensive tools developed specifically to assess 363 
credibility of various types of models in different modelling disciplines. 364 
 365 
The certainty of evidence in each of the model inputs is another critical determinant of the risk of 366 
bias in a model. A model has several types of input data – bodies of evidence used to populate a 367 
model (Table 2). When researchers develop their model de novo, in order to minimize the risk of 368 
bias they need to specify those input parameters to which the model outputs are the most 369 
sensitive. For instance, in economic models these key parameters may include health effects, 370 
resource use, utility values, and baseline risks of outcomes. Model inputs should reflect the entire 371 
body of relevant evidence satisfying clear pre-specified criteria rather than an arbitrarily selected 372 
evidence that is based on convenience (“any available evidence”) or picked in any other non-373 
systematic way (e.g., “first evidence found” – single studies that researchers happen to know 374 
about or are the first hits in a database search).  375 
 376 
The appropriate approach will depend on the type of data and may require performing a 377 
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may have a very narrow inclusion criteria and therefore evidence from single epidemiological 379 
survey or population surveillance may provide all relevant data for the population of interest (e.g. 380 
baseline population incidence or prevalence).  381 
 382 
The certainty of evidence for each input needs to be assessed following the established GRADE 383 
approach specific to that type of evidence (e.g. estimates of intervention effects or baseline risk of 384 
outcomes)[22, 32, 34, 37]. Following the logic of the GRADE approach that the overall certainty of 385 
evidence cannot be higher than the lowest certainty for any body of evidence that is critical for a 386 
decision [51], the overall rating of certainty of evidence across  model inputs should be limited by 387 
the lowest certainty rating for any body of evidence (in this case input data) to which the model 388 
output(s) was proved sensitive. 389 
  390 
Application of this approach requires a priori consideration of likely critical and/or important 391 
inputs when specifying the conceptual ideal target model and the examination of the results of 392 
back-end sensitivity analyses. It further requires deciding how to judge whether results are or are 393 
not sensitive to alternative input parameters.  Authors have described several methods to identify 394 
the most influential parameters including global sensitivity analysis to obtain “parameter 395 
importance measures” (i.e. information based measures) [52];  or alternatively by varying one 396 
parameter at a time and assessing their influence in “base case” outputs [52] For example, in a 397 
model-based economic evaluation one might  be looking for the influence of sensitivity analysis on 398 
cost-effectiveness ratios at a specified willingness-to-pay threshold. 399 
 400 
Indirectness in a single model 401 
By directness or relevance, we mean the extent to which model outputs directly represent the 402 
phenomenon being modelled. To evaluate the relevance of a model, one needs to compare it 403 
against the conceptual ideal target model. When there are concerns about the directness of the 404 
model or there is limited understanding of the system being modelled making it difficult to assess 405 
directness, then one may have lower confidence in model outputs.  406 
 407 
Determining the directness of model outputs includes assessing to what extent the modelled 408 
population, the assumed interventions and comparators, the time horizon, the analytic 409 
perspective, as well as the outcomes being modelled reflect those that are current interest. For 410 
instance, if the question is about the risk of birth defects in children of mothers chronically 411 
exposed to a certain substance, there may be concerns about the directness of the evidence if the 412 
model assumed short-term exposure, the route of exposure was different, or the effects of 413 
exposure to a similar but not the same substance were measured. 414 
 415 
Assessing indirectness in a single model also requires evaluating two separate sources of 416 
indirectness:  417 
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2. indirectness of model outputs with respect to the decision problem at hand. 419 
 420 
This conceptual distinction is important because, although they are interrelated, one needs to 421 
address each type of indirectness separately.  Even if the outputs might be direct to the problem 422 
of interest, the final assessment should consider if the inputs used were also direct for the target 423 
model. 424 
 425 
Using an existing model has potential limitations: its inputs might have been direct for the decision 426 
problem addressed by its developers but are not direct with respect to the problem currently at 427 
hand. In this context, sensitivity analysis can help to assess to what extent model outputs are 428 
robust to the changes in input data or assumptions used in model development.  429 
 430 
Inconsistency in a single model 431 
 432 
A single model may yield inconsistent outputs owing to unexplained variability in the results of 433 
individual studies informing the pooled estimates of input variables. For instance, when 434 
developing a health economic model, a systematic review may yield several credible, but 435 
discrepant, utility estimates in the population of interest. If there is no plausible explanation for 436 
that difference in utility estimates, outputs of a model based on those inputs may also be 437 
qualitatively inconsistent. Again, sensitivity analysis may help to make a judgment to what extent 438 
such inconsistency of model inputs would translate into a meaningful inconsistency in model 439 
outputs with respect to the decision problem at hand.  440 
 441 
Imprecision in a single model 442 
 443 
Sensitivity  analysis characterizes the response of model outputs to parameter variation, and helps 444 
to determine the robustness of model´s qualitative conclusions [52, 53]. The overall certainty of 445 
model outputs may also be lower when the outputs are estimated imprecisely. For quantitative 446 
outputs one should examine not only the point estimate (e.g., average predicted event) but also 447 
the variability of that estimate (e.g., results of the probabilistic sensitivity analysis based in the 448 
distribution of the input parameters). It is essential that a report from a modelling study always 449 
includes information about output variability. Further guidance on how to assess imprecision in 450 
model outputs will need to take into account if the conclusions change according to that specific 451 
parameter. In some disciplines, for instance in environmental health, model inputs are frequently 452 
qualitative. Users of such models may assess “adequacy” of the data, i.e. the degree of “richness” 453 
and quantity of data supporting particular outputs of a model. 454 
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Risk of publication bias in the context of a single model 456 
 457 
The risk of publication bias, also known as “reporting bias”, “non-reporting bias”, or “bias owing to 458 
missing results”, as it is currently called in the Cochrane Handbook [54], is the likelihood that 459 
relevant models have been constructed but were not published or otherwise made publicly 460 
available. Risk of publication bias may not be relevant when assessing the certainty of outputs of a 461 
single model constructed de novo. However, when one intends to reuse an existing model but is 462 
aware or strongly suspects that similar models had been developed but are not available, then 463 
one may be inclined to think that their outputs might have systematically differed from the model 464 
that is available. In such a case, one may have lower confidence in the outputs of the identified 465 
model if there is no reasonable explanation for the inability to obtain those other models.  466 
 467 
Domains that increase the certainty of outputs from a single model 468 
 469 
The GRADE approach to rating the certainty of evidence recognized three situations when the 470 
certainty of evidence can increase: large magnitude of an estimated effect, presence of a dose-471 
response gradient in an estimated effect, and an opposite direction of plausible residual 472 
confounding.[27] Workshop participants agreed that presence of a dose-response gradient in 473 
model outputs may be applicable in some modelling disciplines (e.g., environmental health). 474 
Similarly, whether or not a large magnitude of an effect in model outputs increases the certainty 475 
of the evidence may depend on the modelling discipline. The effect of an opposite direction of  476 
plausible residual confounding seems theoretically also applicable in assessing the certainty of 477 
model outputs (i.e. a conservative model not incorporating input data parameter in favour of an 478 
intervention but still finding favorable outputs) but an actual example of this phenomenon in 479 
modelling studies is still under discussion.  480 
 481 
Assessing the certainty of outputs across multiple models 482 
 483 
Not infrequently, particularly in disciplines relying on mechanistic models, the current knowledge 484 
about the real system being modelled is very limited precluding the ability to determine which of 485 
the available existing models generates higher certainty outputs. Therefore, it may be necessary 486 
to rely on the results across multiple models. Other examples include using multiple models when 487 
no model was developed for the population directly of interest (e.g. the European Breast Cancer 488 
Guideline for Screening and Diagnosis relied on a systematic review of modelling studies that 489 
compared different mammography screening intervals [55]) or when multiple models of the same 490 
situation exist but vary in structure, complexity, and parameter choices (e.g. HIV Modelling 491 
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therapy program and found that all models predicted that the program has the potential to 493 
reduce new HIV infections in the population [56]).   494 
 495 
When researchers choose or are compelled to include outputs from several existing models, they 496 
should assess the certainty of outputs across all included models. This assessment may be more 497 
complex than for single models and single bodies of evidence. The feasibility of GRADE’s guidance 498 
to judge the certainty of evidence lies in the availability of accepted methods for assessing most 499 
bodies of evidence from experimental to observational studies. However, the methods for 500 
systematic reviews of modelling studies are less well-established, some stages of the process are 501 
more complex, the number of highly skilled individuals with experience in such systematic reviews 502 
is far lower, and there is larger variability in the results [57]. Additionally, researchers must be 503 
careful to avoid “double counting” the same model as if it were multiple models. For instance, the 504 
same model (i.e. same structure and assumptions) may have been used in several modelling 505 
studies, in which investigators relied on different inputs. When facing this scenario, researchers 506 
may need to decide which of the inputs are the most direct to their particular question and 507 
include in only this model in the review.   508 
 509 
Risk of bias across multiple models 510 
 511 
The assessment of risk of bias across models involves an assessment of the risk of bias in each 512 
individual model (see above discussion of risk of bias in single model) and subsequently making a 513 
judgement about the overall risk of bias across all included models. Specific methods for 514 
operationalizing this integration remain to be developed. 515 
 516 
Indirectness across multiple models 517 
 518 
As for the risk of bias, researchers need to assess indirectness of outputs initially for each of 519 
included models and then integrate the judgements across models. Likewise, specific methods for 520 
operationalizing this integration still remain to be developed. During this assessment researchers 521 
may find some models too indirect to be informative for their current question and decide to 522 
exclude them from further consideration. However, the criteria to determine which models are 523 
too indirect should be developed a priori, before the search for the models is performed and their 524 
results are known. 525 
 526 
Imprecision across multiple models 527 
 528 
The overall certainty of model outputs may also be lower when model outputs are not estimated 529 
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report the range of estimates and variability of that estimates. When researchers choose to 531 
perform only a qualitative summary of the results across models, it is desirable that they report 532 
some estimate of variability in the outputs of individual models and an assessment of how severe 533 
the variability is (e.g. range of estimated effects). 534 
 535 
Inconsistency of outputs across multiple models 536 
 537 
The assessment of inconsistency should focus on unexplained differences across model outputs 538 
for a given outcome. If multiple existing models addressing the same issue produce considerably 539 
different outputs or reach contrasting conclusions, then careful comparison of the models may 540 
lead to a deeper understanding of the factors that drive outputs and conclusions. Ideally, the 541 
different modelling groups that developed relevant models would come together to explore the 542 
importance of differences in the type and structure of their models, and of the data used as model 543 
inputs.  544 
 545 
Invariably there will be some differences among the estimates from different models. Researchers 546 
will need to assess whether or not these differences are important, i.e. whether they would lead 547 
to different conclusions. If the differences are important but can be explained by model structure, 548 
model inputs, the certainty of the evidence of the input parameters or other relevant reasons, one 549 
may present the evidence separately for the relevant subgroups. If differences are important, but 550 
cannot be clearly explained, the certainty of model outputs may be lower.  551 
 552 
Risk of publication bias across multiple models 553 
 554 
The assessment is similar to that of the risk of publication bias in the context of a single model. 555 
 556 
Domains that increase the certainty of outputs across multiple models 557 
 558 




The goal of the GRADE project group on modelling is to provide concepts and operationalization of 563 
how to rate the certainty of evidence in model outputs. This article provides an overview of the 564 
conclusions of the project group. This work is important because there is a growing need and 565 
availability of modelled information resulting from a steadily increasing knowledge of the 566 
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construct and run models. Users of evidence obtained from modelling studies need to know how 568 
much trust they may have in model outputs. There is a need to improve the methods of 569 
constructing models and to develop methods for assessing the certainty in model outputs. In this 570 
article we have attempted to clarify the most important concepts related to developing and using 571 
model outputs to inform health-related decision-making. Our preliminary work identified 572 
confusion about terminology, lack of clarity of what is a model, and need for methods to assess 573 
certainty in model outputs as priorities to be addressed in order to improve the use of evidence 574 
from modelling studies.  575 
 576 
In some situations, decision-makers might be better off developing a new model specifically 577 
designed to answer their current question. However, we suggest that it is not always feasible to 578 
develop a new model or that developing a new model might not be any better than using already 579 
existing models, when the knowledge of the real life system to be modelled is limited precluding 580 
the ability to choose one model that would be better than any other. Thus, sometimes it may be 581 
necessary or more appropriate to use one or multiple existing models depending on their 582 
availability, credibility, and relevance to the decision-making context. The assessment of the 583 
certainty of model outputs will be conceptually similar when a new model is constructed, or one 584 
existing model is used. The main difference between the latter two approaches is the availability 585 
of information to perform a detailed assessment. That is, information for one’s own model may be 586 
easily accessible, but information required to assess someone else’s model will often be more 587 
difficult to obtain. Assessment of the certainty evidence across models can build on existing 588 
GRADE domains but requires different operationalization.  589 
 590 
Because it builds on an existing, widely used framework that includes a systematic and 591 
transparent evaluation process, modelling disciplines’ adoption of the GRADE approach and 592 
further development of methods to assess the certainty of model outputs may be beneficial for 593 
health decision making. Systematic approaches improve rigor of research, reducing the risk of 594 
error and its potential consequences; transparency of the approach increases its trustworthiness. 595 
There may be additional benefits related to other aspects of the broader GRADE approach, for 596 
instance a potential to reduce unnecessary complexity and workload in modelling by careful 597 
consideration of the most direct evidence as model inputs. This may allow, for instance, 598 
optimization of the use of different streams of evidence as model inputs. Frequently, authors 599 
introduce unnecessary complexity by considering multiple measures of the same outcome when 600 
focus could be on the most direct outcome measure.  601 
 602 
The GRADE working group will continue developing methods and guidance for using model 603 
outputs in health-related decision-making. In subsequent articles we will provide more detailed 604 
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models, integrating the certainty of evidence from various bodies of evidence with credibility of 606 
the model and arriving at the overall certainty in model outputs, how to assess the credibility of 607 
various types of models themselves, and further clarification of terminology. In the future we aim 608 
to develop and publish the detailed guidance for assessing certainty of evidence from models, the 609 
specific guidance for the use of modelling across health care-related disciplines (e.g. toxicology, 610 
environmental health or health economics), validation of the approach, and accompanying 611 
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Structured model representing health care pathways examining effects of an 
intervention on outcomes of interest. 
Types 
 Decision tree models 
 State transition models  
o Markov cohort simulation 
o Individual based microsimulation (first-order Monte Carlo)  
 Discrete event simulation 
 Dynamic transmission models 
 Agent based models 
Examples 
 Estimation of long-term benefits and harms outcomes from complex 
intervention, e.g. minimum unit pricing of alcohol 
 Estimation of benefits and harms of population mammography screening based 
in microsimulation model, e.g. Wisconsin model from CISNET collaboration[58] 
 Susceptible-Infectious-Recovery transmission dynamic model to assess 






Computational models developed to organize, analyse, simulate, visualize or 
predict toxicological and ecotoxicological effects of chemicals. In some cases, these 
models are used to estimate the toxicity of a substance even before it has been 
synthesized. 
Types 
 Structural alerts and rule-based models  
 Read-Across 
 Dose response and Time response 
 Toxicokinetic (TK) and toxicodynamic(TD)  
 Uncertainty factors 
 Quantitative structure activity relationship (QSAR) 
 Biomarker-based toxicity models 
Examples 
• Structural alerts for mutagenicity and skin sensitisation 
• Read-across for complex endpoints such as chronic toxicity 
• Pharmacokinetic (PK) models to calculate concentrations of substances in 
organs, following a variety of exposures QSAR models for carcinogenicity 




The EPA defined these models as: ‘A simplification of reality that is constructed to 
gain insights into select attributes of a physical, biological, economic, or social 
system.’ It involves the application of multidisciplinary knowledge to explain, 
explore and predict the Earth´s response to environmental change, and the 
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Classification (based on the CREM guidance document): 
• Human activity models 
• Natural systems process 
• Emission models 
• Fate and transport models 
• Exposure models 
• Human health effects models 
• Ecological effects models 
• Economic impact models 
• Noneconomic impact models 
Examples 
• Land use regression models 
• IH SkinPerm [60] 
• ConsExpo [61] 
• other exposure models [62] 
Other • HopScore: An Electronic Outcomes-Based Emergency Triage System [63] 
• Computational general equilibrium (CGE) models [64] 
*Although not described in this classification simple calculations incorporating two or more pieces of evidence as 
for example the multiplication of a RR by the baseline risk to obtain the absolute risk difference of an intervention 
is a model, although pragmatic, with their respective assumptions. 
 620 
 621 
Table 2. Selected commonly used and potentially confusing terms used in the context of modelling 622 
and the GRADE approach  623 
 624 
Term General definition 
Sources of evidence 
(may come from in vitro or in vivo experiment or a mathematical model) 
Streams of evidence Parallel information about the same outcome that may have been obtained using 
different methods of estimating that outcome. For instance, evidence of the 
increased risk for developing lung cancer in humans after an exposure to certain 
chemical compound may come from several streams of evidence: 1) mechanistic 
evidence – models of physiological mechanisms, 2) studies in animals – observations 
and experiments in animals from different phyla, classes, orders, families, genera, 
and species (e.g., bacteria, nematodes, insects, fish, mice, rats), and 3) studies in 
humans.  
Bodies of evidence Information about multiple different aspects around a decision about the best 
course of action. For instance, in order to decide whether or not a given diagnostic 
test should be used in some people, one needs to integrate the bodies of evidence 
about: the accuracy of the test, the prevalence of the conditions being suspected, 
the natural history of these conditions, the effects of potential treatments, values 
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(may refer to many concepts, thus alternative terms are preferred to reduce confusion) 




▪ certainty of modelled 
evidence 
▪ quality of evidence 
▪ quality of model 
output  
▪ strength of evidence 
▪ confidence in model 
outputs 
In the context of health decision-making, the certainty of evidence (term preferred 
over “quality” in order to avoid confusion with the risk of bias in an individual study) 
reflects the extent to which one’s confidence in an estimate of an effect is adequate 
to make a decision or a recommendation. Decisions are influenced not only by the 
best estimates of the expected desirable and undesirable consequences but also by 
one’s confidence in these estimates. In the context of evidence syntheses of 
separate bodies of evidence (e.g., systematic reviews), the certainty of evidence 
reflects the extent of confidence that an estimate of effect is correct. For instance, 
the attributable national risk of cardiovascular mortality resulting from exposure to 
air pollution measured in selected cities. 
The GRADE Working Group published several articles explaining the concept in 
detail.[22-28, 65] Note that the phrase “confidence in an estimate of an effect” does 
not refer to statistical confidence intervals. Certainty of evidence is always assessed 
for the whole body of evidence rather than on a single study level (single studies are 
assessed for risk of bias and indirectness). 




▪ quality of model 
inputs 
Characteristics of data that are used to develop, train, or run the model, e.g., source 
of input values, their manipulation prior to input into a model, quality control, risk of 
bias in data, etc. 
Credibility of a model 
 
Alternative terms: 
▪ quality of a model 
▪ risk of bias in a 
model 
▪ validity of a model 
To avoid confusion and keep with terminology used by modelling community[7] we 
suggest using the term credibility rather than quality of a model. The concept refers 
to the characteristics of a model itself – its design or execution – that affect 
the risk that the results may overestimate or underestimate the true effect. Various 
factors influence the overall credibility of a model, such as its structure, the analysis 
and the validation of the assumptions made during modelling. 
Quality of reporting Refers to how comprehensively and clearly model inputs, a model itself, and model 
outputs have been documented and described such that they can be critically 
evaluated and used for decision-making. Quality of reporting and quality of a model 
are separate concepts: a model with a low quality of reporting is not necessarily a 
low-quality model and vice versa. 
Directness  









By directness of a model we mean the extent to which the model represents the 
real-life situation being modelled which is dependent on how well the input data and 
the model structure reflect the scenario of interest. 
Directness is the term used in the GRADE approach, because each of the alternatives 
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* There may be either subtle or fundamental differences among some disciplines in how these 626 
terms are being used; for the purposes of this article, these terms are generalized rather than 627 
discipline specific. 628 
 629 
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Figure 1. The general approach to using modelled evidence and assessing its certainty in health-631 
related disciplines. 632 
 633 
 634 
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Appendix. List of workshop participants 636 
 637 
Elie Akl (EA)– American University of Beirut, Lebanon 638 
Jim Bowen (JMB)– McMaster University, Canada 639 
Chris Brinkerhoff (CB)– US Environmental Protection Agency, USA 640 
Jan Brozek (JLB)– McMaster University, Canada 641 
John Bucher (JB)– US National Toxicology Program, USA 642 
Carlos Canelo-Aybar (CCA)– Iberoamerican Cochrane Centre, Spain 643 
Marcy Card (MC)– US Environmental Protection Agency, USA 644 
Weihsueh A. Chiu (WCh)– Texas A&M University, USA 645 
Mark Cronin (MC)– Liverpool John Moores University, UK 646 
Tahira Devji (TD)– McMaster University, Canada 647 
Ben Djulbegovic (BD)– University of South Florida, USA 648 
Ken Eng (KE)– Public Health Agency of Canada 649 
Gerald Gartlehner (GG)– Donau-Universität Krems, Austria 650 
Gordon Guyatt (GGu)– McMaster University, Canada 651 
Raymond Hutubessy (RH)– World Health Organization Initiative for Vaccine Research, Switzerland 652 
Manuela Joore (MJ)– Maastricht University, the Netherlands 653 
Richard Judson (RJ)– US Environmental Protection Agency, USA 654 
S. Vittal Katikireddi (SK)– University of Glasgow, UK 655 
Nicole Kleinstreuer (NK)– US National Toxicology Program, USA 656 
Judy LaKind (JL)– University of Maryland, USA 657 
Miranda Langendam (ML)– University of Amsterdam, the Netherlands 658 
Zbyszek Leś (ZL)– Evidence Prime Inc., Canada 659 
Veena Manja (VM)– McMaster University, Canada 660 
Joerg Meerpohl (JM)– GRADE Center Freiburg, Cochrane Germany, University Medical Center 661 
Freiburg 662 
Dominik Mertz (DM)– McMaster University, Canada 663 
Roman Mezencev (RM)– US Environmental Protection Agency, USA 664 
Rebecca Morgan (RMo)– McMaster University, Canada 665 
Gian Paolo Morgano (GPM)– McMaster University, Canada 666 
Reem Mustafa (RMu)– University of Kansas, USA 667 
Bhash Naidoo (BN)– National Institute for Health and Clinical Excellence, UK 668 
Martin O'Flaherty (MO)– Public Health and Policy, University of Liverpool, UK 669 
Grace Patlewicz (GP)– US Environmental Protection Agency, USA 670 
John Riva (JR)– McMaster University, Canada 671 
Alan Sasso (AS)– US Environmental Protection Agency, USA 672 
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Holger Schünemann (HJS)– McMaster University, Canada 674 
Lisa Schwartz (LS)– McMaster University, Canada 675 
Ian Shemilt (IS)– University College London, UK 676 
Marek Smieja (MS)– McMaster University, Canada 677 
Ravi Subramaniam (RS)– US Environmental Protection Agency, USA 678 
Jean-Eric Tarride (JT)– McMaster University, Canada 679 
Kris Thayer (KAT)– US Environmental Protection Agency, USA 680 
Katya Tsaioun (KT)– John Hopkins University, USA 681 
Bernhard Ultsch (BU)– Robert Koch Institute, Germany 682 
John Wambaugh (JW)– US Environmental Protection Agency, USA 683 
Jessica Wignall (JWi)– ICF, USA 684 
Ashley Williams (AW)– ICF, USA 685 
Feng Xie (FX)– McMaster University, Canada 686 
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What is new 
 
1. General concepts determining the certainty of evidence in the GRADE approach (risk of bias, 
indirectness, inconsistency, imprecision, reporting bias, magnitude of an effect, dose-
response relation, and the direction of residual confounding) also apply in the context of 
assessing the certainty of evidence from models (model outputs).  
2. Detailed assessment of the certainty of evidence from models differs for the assessment of 
outputs from a single model compared to the assessment of outputs across multiple 
models.  
3. We propose a framework for selecting the best available evidence from models to inform 
health care decisions: to develop a model de novo, to identify an existing model the outputs 
of which provide the highest certainty evidence, or to use outputs from multiple models. 
4. We suggest that the modelling and health care decision making communities collaborate 
further to clarify terminology used in the context of modelling and make it consistent across 
the disciplines to facilitate communication. 
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